Cellares and City of Hope launched a collaboration to evaluate automated manufacturing and QC platforms for City of Hope’s investigational CAR T program targeting glioblastoma multiforme. City of Hope will pilot Cellares’ Cell Shuttle manufacturing platform and Cell Q quality control automation at preclinical stages to establish reproducible, scalable processes intended to support later clinical expansion. The partnership seeks to remove manual bottlenecks that limit throughput for solid‑tumor CAR‑T therapies, standardize analytics, and reduce failure rates. City of Hope stressed the need for repeatable manufacturing to translate glioblastoma CAR‑T programs into broader clinical trials.